KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Short-term Investments: 2009-2025

Historic Short-term Investments for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $589.0 million.

  • Acadia Pharmaceuticals' Short-term Investments rose 43.60% to $589.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $589.0 million, marking a year-over-year increase of 43.60%. This contributed to the annual value of $436.4 million for FY2024, which is 74.42% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Short-term Investments stood at $589.0 million for Q3 2025, which was up 15.87% from $508.4 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Short-term Investments ranged from a high of $589.0 million in Q3 2025 and a low of $112.0 million during Q1 2023.
  • Its 3-year average for Short-term Investments is $352.3 million, with a median of $323.8 million in 2024.
  • Its Short-term Investments has fluctuated over the past 5 years, first tumbled by 53.55% in 2023, then spiked by 137.35% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Short-term Investments (Quarterly) stood at $373.3 million in 2021, then declined by 19.10% to $302.0 million in 2022, then declined by 17.14% to $250.2 million in 2023, then skyrocketed by 74.42% to $436.4 million in 2024, then spiked by 43.60% to $589.0 million in 2025.
  • Its Short-term Investments stands at $589.0 million for Q3 2025, versus $508.4 million for Q2 2025 and $463.9 million for Q1 2025.